HPB (Oxford). 2009 Nov;11(7):551-8. doi: 10.1111/j.1477-2574.2009.00084.x.
Treating patients with hepatocellular carcinoma (HCC) remains a challenge, especially when the disease presents at an advanced stage. The aim of this retrospective study was to determine the efficacy of liver resection in patients who fulfil or exceed University of California San Francisco (UCSF) criteria by assessing longterm outcome.
Between 2002 and 2008, 59 patients with large HCC (>5 cm) underwent hepatectomy. Thirty-two of these patients fulfilled UCSF criteria for transplantation (group A) and 27 did not (group B). Disease-free survival and overall survival rates were compared between the two groups after resection and were critically evaluated with regard to patient eligibility for transplant.
In all patients major or extended hepatectomies were performed. There was no perioperative mortality. Morbidity consisted of biliary fistula, abscess, pleural effusion and pneumonia and was significantly higher in patient group B. Disease-free survival rates at 1, 3 and 5 years were 66%, 37% and 34% in group A and 56%, 29% and 26% in group B, respectively (P < 0.01). Survival rates at 1, 3 and 5 years were 73%, 39% and 35% in group A and 64%, 35% and 29% in group B, respectively (P= 0.04). The recurrence rate was higher in group B (P= 0.002).
Surgical resection, if feasible, is suggested in patients with large HCC and can be performed with acceptable overall and disease-free survival and morbidity rates. In patients eligible for transplantation, resection may also have a place in the management strategy when waiting list time is prolonged for reasons of organ shortage or when the candidate has low priority as a result of a low MELD (model for end-stage liver disease) score.
治疗肝细胞癌(HCC)患者仍然是一个挑战,尤其是当疾病处于晚期时。本回顾性研究的目的是通过评估长期结果来确定符合或超过加利福尼亚大学旧金山分校(UCSF)标准的患者行肝切除术的疗效。
2002 年至 2008 年间,59 例大肝癌(>5cm)患者接受了肝切除术。其中 32 例患者符合 UCSF 移植标准(A 组),27 例不符合(B 组)。切除后比较两组患者的无病生存率和总生存率,并根据患者的移植资格对其进行严格评估。
所有患者均行主要或扩大肝切除术。无围手术期死亡。并发症包括胆瘘、脓肿、胸腔积液和肺炎,B 组患者的发病率明显更高。A 组患者的 1、3 和 5 年无病生存率分别为 66%、37%和 34%,B 组分别为 56%、29%和 26%(P<0.01)。A 组患者的 1、3 和 5 年生存率分别为 73%、39%和 35%,B 组分别为 64%、35%和 29%(P=0.04)。B 组的复发率更高(P=0.002)。
如果可行,对于大肝癌患者,建议进行手术切除,其总生存率和无病生存率以及发病率均可以接受。对于符合移植条件的患者,当因器官短缺而延长等待名单时间或由于低 MELD(终末期肝病模型)评分导致候选者优先级较低时,切除术也可能在管理策略中占有一席之地。